View detailed information about this source submission and its extracted claims.
Complete details about this source submission.
{ "source_type": "extension", "content_hash": "77a7a05ba7fae1a65f604ba433b73f295a8aa5c05da800a58da0c9292114fb1f", "submitted_via": "chrome_extension", "extension_version": "1.0.18" }
<html lang="en" class="story nytapp-vi-article nytapp-vi-story story nytapp-vi-article " data-nyt-compute-assignment="fallback" xmlns:og="http://opengraphprotocol.org/schema/" data-rh="lang,class"><head> <meta charset="utf-8"> <title>How MDMA and Psilocybin Became Hot Investments - The New York Times</title> <meta data-rh="true" name="robots" content="noarchive, max-image-preview:large"><meta data-rh="true" name="description" content="Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences."><meta data-rh="true" property="twitter:url" content="https://www.nytimes.com/2021/05/09/health/psychedelics-mdma-psilocybin-molly-mental-health.html"><meta data-rh="true" property="twitter:title" content="The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same. (Published 2021)"><meta data-rh="true" property="twitter:descr...
Detailed status of each processing step.
All claims extracted from this source document.
Claims will appear here once processing is complete.